These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 22282906)

  • 21. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factors in 41 consecutive Asian patients.
    Tai WM; Quah D; Yap SP; Tan SH; Tang T; Tay KW; Koo YX; Tao M; Quek R; Lim ST
    Leuk Lymphoma; 2011 Apr; 52(4):604-12. PubMed ID: 21261504
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study.
    Martelli M; Ceriani L; Zucca E; Zinzani PL; Ferreri AJ; Vitolo U; Stelitano C; Brusamolino E; Cabras MG; Rigacci L; Balzarotti M; Salvi F; Montoto S; Lopez-Guillermo A; Finolezzi E; Pileri SA; Davies A; Cavalli F; Giovanella L; Johnson PW
    J Clin Oncol; 2014 Jun; 32(17):1769-75. PubMed ID: 24799481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).
    Mamot C; Klingbiel D; Hitz F; Renner C; Pabst T; Driessen C; Mey U; Pless M; Bargetzi M; Krasniqi F; Gigli F; Hany T; Samarin A; Biaggi C; Rusterholz C; Dirnhofer S; Zucca E; Martinelli G
    J Clin Oncol; 2015 Aug; 33(23):2523-9. PubMed ID: 26150440
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
    Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.
    Vitolo U; Trněný M; Belada D; Burke JM; Carella AM; Chua N; Abrisqueta P; Demeter J; Flinn I; Hong X; Kim WS; Pinto A; Shi YK; Tatsumi Y; Oestergaard MZ; Wenger M; Fingerle-Rowson G; Catalani O; Nielsen T; Martelli M; Sehn LH
    J Clin Oncol; 2017 Nov; 35(31):3529-3537. PubMed ID: 28796588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma.
    Oki Y; Westin JR; Vega F; Chuang H; Fowler N; Neelapu S; Hagemeister FB; McLaughlin P; Kwak LW; Romaguera JE; Fanale M; Younes A; Rodriguez MA; Orlowski RZ; Wang M; Ouzounian ST; Samaniego F; Fayad L
    Br J Haematol; 2013 Dec; 163(5):611-20. PubMed ID: 24117234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of rituximab and radiotherapy for patients with primary mediastinal large B-cell lymphoma receiving doxorubicin-containing chemotherapy.
    Xu LM; Fang H; Wang WH; Jin J; Wang SL; Liu YP; Song YW; Ren H; Zhou LQ; Li YX
    Leuk Lymphoma; 2013 Aug; 54(8):1684-90. PubMed ID: 23137070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients who failed cyclophosphamide, adriamycin, vincristine, and prednisone.
    Chen YB; Hochberg EP; Feng Y; Neuberg D; Rawal B; Motyckova G; Fisher DC; McAfee SL; Spitzer TR; Lacasce AS
    Leuk Lymphoma; 2010 May; 51(5):789-96. PubMed ID: 20367136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
    Thieblemont C; Tilly H; Gomes da Silva M; Casasnovas RO; Fruchart C; Morschhauser F; Haioun C; Lazarovici J; Grosicka A; Perrot A; Trotman J; Sebban C; Caballero D; Greil R; van Eygen K; Cohen AM; Gonzalez H; Bouabdallah R; Oberic L; Corront B; Choufi B; Lopez-Guillermo A; Catalano J; Van Hoof A; Briere J; Cabeçadas J; Salles G; Gaulard P; Bosly A; Coiffier B
    J Clin Oncol; 2017 Aug; 35(22):2473-2481. PubMed ID: 28426350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma.
    Wöhrer S; Püspök A; Drach J; Hejna M; Chott A; Raderer M
    Ann Oncol; 2004 Jul; 15(7):1086-90. PubMed ID: 15205203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy.
    Binkley MS; Hiniker SM; Wu S; Natkunam Y; Mittra ES; Advani RH; Hoppe RT
    Leuk Lymphoma; 2016; 57(3):604-8. PubMed ID: 26159046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era.
    Kumar A; Lunning MA; Zhang Z; Migliacci JC; Moskowitz CH; Zelenetz AD
    Br J Haematol; 2015 Dec; 171(5):776-83. PubMed ID: 26456939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
    Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
    Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Standard CHOP immuno-chemotherapy for primary mediastinal lymphomas].
    Schneider T; Tóth E; Lovey J; Molnár Z; Deák B; Várady E; Csomor J; Matolcsy A; Lengyel Z; Petri K; Gaudi I; Rosta A
    Orv Hetil; 2011 May; 152(19):735-42. PubMed ID: 21498163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patients.
    Broccoli A; Casadei B; Stefoni V; Pellegrini C; Quirini F; Tonialini L; Morigi A; Marangon M; Argnani L; Zinzani PL
    BMC Cancer; 2017 Apr; 17(1):276. PubMed ID: 28415982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma.
    Kayamori K; Shono K; Onoda M; Yokota A
    Hematology; 2019 Dec; 24(1):52-59. PubMed ID: 30101679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies.
    Vassilakopoulos TP; Papageorgiou SG; Angelopoulou MK; Chatziioannou S; Prassopoulos V; Karakatsanis S; Arapaki M; Mellios Z; Sachanas S; Kalpadakis C; Katodritou E; Leonidopoulou T; Kotsianidis I; Hatzimichael E; Kotsopoulou M; Dimou M; Variamis E; Boutsis D; Terpos E; Michali E; Karianakis G; Tsirkinidis P; Vadikolia C; Poziopoulos C; Pigaditou A; Vrakidou E; Siakantaris MP; Kyrtsonis MC; Symeonidis A; Anargyrou K; Papaioannou M; Chatziharissi E; Vervessou E; Tsirogianni M; Palassopoulou M; Gainaru G; Mainta C; Tsirigotis P; Assimakopoulou T; Konstantinidou P; Papadaki H; Dimopoulos MA; Pappa V; Karmiris T; Roussou P; Datseris I; Panayiotidis P; Konstantopoulos K; Pangalis GA; Rondogianni P
    Ann Hematol; 2021 Sep; 100(9):2279-2292. PubMed ID: 33523289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium.
    Hainsworth JD; Flinn IW; Spigel DR; Clark BL; Griner PL; Vazquez ER; Doss HH; Shipley D; Franco LA; Burris HA; Greco FA;
    Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):44-50. PubMed ID: 20223728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).
    Mounier N; Briere J; Gisselbrecht C; Emile JF; Lederlin P; Sebban C; Berger F; Bosly A; Morel P; Tilly H; Bouabdallah R; Reyes F; Gaulard P; Coiffier B
    Blood; 2003 Jun; 101(11):4279-84. PubMed ID: 12576316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma.
    Avigdor A; Sirotkin T; Kedmi M; Ribakovsy E; Berkowicz M; Davidovitz Y; Kneller A; Merkel D; Volchek Y; Davidson T; Goshen E; Apter S; Shimoni A; Ben-Bassat I; Nagler A
    Ann Hematol; 2014 Aug; 93(8):1297-304. PubMed ID: 24595734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.